About

Patricia M. Danzon is the Celia Moh Professor at The Wharton School, University of Pennsylvania. She holds a B.A. from Oxford University and a Ph.D. in Economics from the University of Chicago. Her academic career includes faculty positions at Duke University and the University of Chicago. Professor Danzon is an internationally recognized expert in the fields of economics of health care, the biopharmaceutical industry, and insurance. She is a member of the Institute of Medicine and the National Academy of Social Insurance, and a Research Associate at the National Bureau of Economic Research. Her research interests encompass biopharmaceuticals, health care, industrial organization, insurance, and liability, with a focus on the economics of law and policy related to health care and pharmaceuticals. She has served as a consultant to numerous governmental agencies, NGOs, and private corporations both in the US and internationally. Additionally, she has held leadership roles on various boards, including the Board of Directors of Medarex, Inc., and has served as an associate editor for prominent economic and health economics journals.

Research topics

• Economics
• Computer Science
• Finance
• Humanities
• Business
• Political Science
• Industrial organization
• Medicine
• Mathematics
• Welfare economics
• Philosophy
• Microeconomics
• Pharmacology

Selected publications

• Firm Size and Pharmaceutical Mergers: A Cross-National, Cross-Sector Perspective

  SSRN Electronic Journal · 2021

  1st authorCorresponding
  • Computer Science
  • Business
  • Industrial organization
  PublisherDOI

• The Neglected Concern of Firm Size in Pharmaceutical Mergers

  SSRN Electronic Journal · 2021 · 3 citations

  1st authorCorresponding
  • Business
  • Industrial organization
  • Economics
  PublisherDOI

• Firm size and pharmaceutical mergers: A cross-national, cross-sector perspective

  Concurrences Review · 2021

  1st authorCorresponding
  • Political Science
  • Humanities
  • Political Science

  L'analyse standard des fusions, qui se concentre sur le potentiel de la fusion proposee a augmenter les prix ou a reduire l'innovation sur les marches de produits individuels, ignore le potentiel des…

  Publisher

• Antitrust In Life Sciences - Webinar #3: Do Pharmaceutical Mergers Harm Consumers?

  2020-07-02

  article

  Webinar part of the Antitrust in Life Sciences conference organized by Concurrences and Fordham University, with Max Miller (Iowa Attorney General's Office), Patricia Danzon (The Wharton…

  Publisher

• Market Incentives and the Costs of Medical Malpractice

  2019-06-03

  book-chapter1st authorCorresponding

  Since the early 1970s, claim severity has consistently risen faster than both general consumer prices and medical care costs. Liability for negligence can in principle provide a useful corrective to inadequate market incentives for care. Since 1984, there has been talk of a new medical malpractice crisis—less than a decade since the malpractice crisis of the mid-1970s. The visible costs of malpractice insurance are probably small compared with the less visible costs of malpractice: the injuries that occur because of medical negligence. The malpractice system performs two primary functions: deterrence of medical negligence and compensation of its victims. An indirect response to the rising threat of suit is that the medical profession has become more active in other forms of quality control, such as disciplinary actions through boards of medical quality assurance and hospital peer review committees. Many states have general arbitration statutes, and others have enacted legislation specifically enabling binding arbitration of medical malpractice claims.

  PublisherDOI

• Specific Value Assessment Considerations

  Value in Health · 2019-06-01 · 4 citations

  articleOpen accessSenior author
  PublisherOA PDFDOI

• Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]

  Value in Health · 2018-02-01 · 91 citations

  articleOpen accessSenior author
  PublisherOA PDFDOI

• Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]

  Value in Health · 2018-02-01 · 521 citations

  articleSenior author
  PublisherDOI

• Drug Pricing and Value in Oncology

  Recent results in cancer research/Recent Results in Cancer Research · 2018-12-12 · 9 citations

  review1st authorCorresponding
  PublisherDOI

• Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues

  PharmacoEconomics · 2018-07-30 · 63 citations

  article1st authorCorresponding
  PublisherDOI

Recent grants

• NIH Grant T32HS000009

  NIH · $7.4M · 2013

Frequent coauthors

• Adrian Towse

  Office Of Health Economics

  37 shared

• Sean Nicholson

  Policy Analysis (United States)

  23 shared

• Andrew J. Epstein

  20 shared

• Mark V. Pauly

  National Bureau of Economic Research

  14 shared

• Nuno Sousa Pereira

  12 shared

• Andrew Mulcahy

  RAND Corporation

  12 shared

• J. Mestre-Ferrandiz

  Universidad Carlos III de Madrid

  12 shared

• Jeffrey S. McCullough

  University of Michigan–Ann Arbor

  11 shared

Awards & honors

• Agency for Health Care Research and Quality, John M.. Eisenb…
• American Risk and Insurance Association, Award for Outstandi…
• American Association of Risk and Insurance, Award for Outsta…
• American Risk and Insurance Association, Elizur Wright Award…